Can better HER2 classification improve breast cancer care?
NCT ID NCT07758127
First seen Aug 11, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This study looks at breast cancer tumors to understand HER2 levels, including low and ultra-low expressions, which may affect treatment choices. Researchers will examine tissue samples from 100 patients diagnosed in Sohag, Egypt, and compare HER2 status with other tumor features like grade and lymph node involvement. The goal is to improve how HER2 is scored and interpreted, potentially leading to more personalized care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- This could lead to more precise classification of breast cancer subtypes, helping doctors tailor treatments more effectively.
- What could go wrong
- This is an observational study, so it won't directly test a treatment. Results may not apply beyond the local population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of medicine sohag university
Sohag, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?